343564-56-7

Usage

InChI:InChI=1/C9H9BrFNO2/c1-12(14-2)9(13)6-3-4-7(10)8(11)5-6/h3-5H,1-2H3

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 695188-21-7 4-bromo-3-fluorobenzoyl chloride 

Downstream Products

• 916792-04-6 1-(4-bromo-3-fluoro-phenyl)-propan-1-one 
• 304445-49-6 1-(4-bromo-3-fluorophenyl)ethan-1-one 
• 343564-57-8 1-(4-bromo-3-fluorophenyl)-1-butanone 
• 956037-85-7 4-bromo-3-fluoro-4'-methylbenzophenone 
• 1022154-78-4 (4-acetyl-2-fluorophenyl)boronic acid 
• 1006875-89-3 1-(4-bromo-3-fluorophenyl)-2,2-dihydroxyethanone 
• 1029714-83-7 2-(4-bromo-3-fluorophenyl)-2-oxoacetaldehyde 
• 1006875-90-6 1-(4-bromo-3-fluorophenyl)-2,2-diethoxyethanone 
• 1029714-84-8 6-(4-bromo-3-fluorophenyl)-1,2,4-triazin-3-amine 
• 1029714-86-0 6-((2-(4-bromo-3-fluorophenyl)imidazo[1,2-b][1,2,4]triazin-7-yl)methyl)quinoline 
• 1029714-87-1 2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzonitrile 
• 1332952-19-8 2-fluoro-N-[(2R)-2-hydroxypropyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide 
• 1003879-02-4 2-bromo-1-(4-bromo-3-fluorophenyl)ethanone 
• 1388826-03-6 (4-bromo-3-fluorophenyl)(4-(tetrahydro-2H-pyran-2-yloxy)-phenyl)methanone 

Relevant academic research and scientific papers

ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR

Disclosed are compounds inhibiting the conversion of α–KG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition c

NOVEL BENZIMIDAMIDES COMPOUNDS COMPRISING AN OXABORININ RING

The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) cau

PIPERIDINE COMPOUNDS AS PCSK9 INHIBITORS

One aspect of the invention relates to a series of new PCSK9 inhibitor compounds comprising piperidine ring structures, including compounds of formula (I) and/or pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating PCSK9 receptor related diseases comprising administration of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.

HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.

Synthesis method of 3-fluoro-4-bromo-acetophenone

The invention relates to a synthesis method of 3-fluoro-4-bromo-acetophenone. The method includes: taking 3-fluoro-4-bromo-benzoyl chloride, dimethylhydroxyamine hydrochloride and methylmagnesium chloride as the raw materials, carrying out aminolysis, ext

NOVEL AROMATIC COMPOUND AND USE THEREOF

Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of Formula (I) and (II) wherein R1, R2, R3, R6, A and A' are defined herein. The compounds are useful as inhibitors of the function of NS5A protein encoded by HCV for the treatment of hepatitis C viral infection.

IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS

The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.